Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer
June 12 2018 - 8:00AM
Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision
medicine for oncology through molecular markers and diagnostics,
today announced the appointment Michael McCartney as the Company’s
Chief Commercial Officer, effective immediately. Mr. McCartney will
be responsible for developing and overseeing Cancer Genetics’
commercial strategy and spearheading the Company’s business
development initiatives.
Mr. McCartney has more than 20 years of life sciences,
diagnostic and lab services industry experience with senior level
responsibilities in sales management, global marketing and business
development. Prior to joining Cancer Genetics, Mr. McCartney served
as the Chief Executive Officer at SciKon Innovation, Inc., an
early-stage life science company, where he was responsible for
guiding the company through fundraising activities as well as
developing and executing an exit strategy for the company. Prior to
his appointment as CEO, Michael served as Chief Operating Officer
at SciKon, where he was responsible for developing the sales and
marketing organizations, creating the overall sales process,
strategic direction, as well as company and individual goals. Early
in his career, Mr. McCartney held positions across multiple
disciplines at BioAgilytix Labs, Roche, Siemens and Abbott.
Mr. McCartney holds a Master of Business Administration degree
from LaSalle University in Philadelphia and a Bachelor’s degree in
Business Administration with an emphasis on finance from Indiana
University of Pennsylvania.
“We are excited to welcome Michael to Cancer Genetics as we
execute on our plans to transform the business to accelerate the
path to profitability by expanding revenues in our Biopharma and
Discovery businesses in the near term,” said John A. Roberts, Chief
Executive Officer of Cancer Genetics. “Michael’s leadership and
expertise in sales and marketing management and commercial strategy
development will be instrumental in driving sustainable growth for
our Company.”
“The team at Cancer Genetics’ is committed to leveraging its
expertise in developing advanced assays and tests, especially in
the immuno-oncology arena, to continue transforming cancer
diagnosis and treatment, and empowering our biopharma partners’
development efforts,” said Mr. McCartney. “I am pleased to be a
part of the team and look forward to building and executing
commercial and business initiatives focused on bringing important
new tests and services to biopharma and biotech companies that
enhance the development of drugs designed to improve patient
outcomes."
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine
in oncology by partnering with leading pharmaceutical and
biotechnology companies developing novel treatments to fight cancer
and supporting physicians providing direct patient care through the
use of oncology biomarkers and molecular testing. CGI has developed
a global footprint with locations in the US, Australia, India and
China. We have established strong clinical research collaborations
with leading biopharma companies and major cancer centers such as
Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, USC
Norris Comprehensive Cancer Center, Tisch Cancer
Institute at Mount Sinai and the National Cancer Institute among
others.
The Company offers a comprehensive array of oncology-focused
services that provide critical genomic and biomarker information.
The Company’s team of medical and scientific experts delivers
clinical laboratory services from CLIA-certified and CAP-accredited
laboratories in the US with licensure from several states,
including New York State; and preclinical services, including
animal studies, from GLP-compliant audited facilities.
For more information, please visit or follow CGI
at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to future financial
and/or operating results, future growth in revenues, margins,
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. tests and services, along
with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, risks
of cancellation of customer contracts or bookings or discontinuance
of trials, risks that anticipated benefits from acquisitions will
not be realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights, uncertainty of
collections from Medicare and third party payors for novel tests
and services and other risks discussed in the Cancer Genetics, Inc.
Form 10-K for the year ended December 31, 2016 along with other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics, Inc. disclaims any obligation to update these
forward-looking statements.
Investor Contacts:Lee Roth / Carol Ruth The
Ruth GroupTel: 646-536-7012 / 7004Email: lroth@theruthgroup.com /
cruth@theruthgroup.com
Media Contact:Kirsten ThomasThe Ruth GroupTel:
508-280-6592Email: kthomas@theruthgroup.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2023 to Aug 2024